Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

BASF discloses protein kinase inhibitors useful as antiangiogenic agents

Nov. 25, 1999

Calcium entry blockers with potential in the treatment of prostate cancer

Nov. 25, 1999

Valentis initiates phase IIa trial of IFN-alpha gene medicine in angiosarcoma

Nov. 25, 1999

Combination therapy containing GTI-2040 shows remarkable antitumor activity

Nov. 25, 1999

More promising cancer news from AACR-NCI-EORTC: Hughes Institute presents new compounds

Nov. 24, 1999

Radicicol derivative KF-58333 is a promising antileukemia agent

Nov. 24, 1999

European screening program identifies novel anticancer drug candidate

Nov. 24, 1999

Bayer presents novel camptothecin glycoconjugates at AACR-NCI-EORTC meeting

Nov. 24, 1999

VEGF receptor tyrosine kinase inhibitor PTK-787 is a potent antiangiogenic agent

Nov. 24, 1999

U.S. academic team takes a novel approach to treating prostate cancer

Nov. 24, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...